Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Non-cash Items (2016 - 2021)

ImmunityBio (IBRX) has disclosed Non-cash Items for 8 consecutive years, with $16.2 million as the latest value for Q2 2021.

  • Quarterly Non-cash Items rose 575.0% to $16.2 million in Q2 2021 from the year-ago period, while the trailing twelve-month figure was $16.2 million through Jun 2021, up 575.0% year-over-year, with the annual reading at $29.7 million for FY2020, 420.95% up from the prior year.
  • Non-cash Items for Q2 2021 was $16.2 million at ImmunityBio, down from $54.3 million in the prior quarter.
  • The five-year high for Non-cash Items was $54.3 million in Q1 2021, with the low at $353000.0 in Q2 2019.
  • Average Non-cash Items over 5 years is $9.5 million, with a median of $5.8 million recorded in 2017.
  • The sharpest move saw Non-cash Items plummeted 95.28% in 2018, then soared 1659.45% in 2021.
  • Over 5 years, Non-cash Items stood at $11.9 million in 2017, then tumbled by 95.28% to $563000.0 in 2018, then soared by 914.21% to $5.7 million in 2019, then surged by 420.95% to $29.7 million in 2020, then tumbled by 45.54% to $16.2 million in 2021.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $16.2 million, $54.3 million, and $29.7 million for Q2 2021, Q1 2021, and Q4 2020 respectively.